XOMA Royalty (LTS:0M26) Change In Inventory : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is XOMA Royalty Change In Inventory?

XOMA Royalty's change in inventory for the quarter that ended in Dec. 2024 was $0.00 Mil. It means XOMA Royalty's inventory stayed the same from Sep. 2024 to Dec. 2024 .

XOMA Royalty's change in inventory for the fiscal year that ended in Dec. 2024 was $0.00 Mil. It means XOMA Royalty's inventory stayed the same from Dec. 2023 to Dec. 2024 .

XOMA Royalty's Total Inventories for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. XOMA Royalty's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.

XOMA Royalty Change In Inventory Historical Data

The historical data trend for XOMA Royalty's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty Change In Inventory Chart

XOMA Royalty Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

XOMA Royalty Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

XOMA Royalty Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

XOMA Royalty (LTS:0M26) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

XOMA Royalty's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

XOMA Royalty's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

XOMA Royalty's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	2.342
	=	0.00

XOMA Royalty Change In Inventory Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA Royalty Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (LTS:0M26) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

XOMAO.PFD:USA XOMAP.PFD:USA XOMA:USA X0M1:Germany

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

XOMA Royalty Headlines

No Headlines